Abstract CT115: Phase 1b open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in combination with sintilimab (anti-PD1) in patients with advanced microsatellite stable (MSS) colorectal,gastroesophageal or ovarian cancer
Mark Wong, Jia Liu(Sun Yat-sen University), Shehara Mendis, Niall C. Tebbutt(Austin Health), Rafid Al-Asady(Westmead Hospital), Oksana Zdanska(Sirtex (Australia)), Eugene Hsu(St Vincent's Hospital Melbourne), Darren R. Shafren(Sirtex (Australia)), Timothy Price(Basil Hetzel Institute)
Cited by 0
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
|Science Translational Medicine|2016|1.5k